Validated using a knockout cell line
Recombinant
RabMAb

Anti-ErbB 3 antibody [E186] (ab32121)

Overview

  • Product name
    Anti-ErbB 3 antibody [E186]
    See all ErbB 3 primary antibodies
  • Description
    Rabbit monoclonal [E186] to ErbB 3
  • Specificity
    ab32121 recognises ErbB3/HER3.
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: ICC/IF,IHC or IP
  • Species reactivity
    Reacts with: Rat, Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human ErbB 3 aa 1300 to the C-terminus (C terminal).
    Database link: P21860

  • Positive control
    • MCF-7 cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab32121 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 185 kDa (predicted molecular weight: 149 kDa).
  • Application notes
    Is unsuitable for ICC/IF,IHC or IP.
  • Target

    • Function
      Binds and is activated by neuregulins and NTAK.
    • Tissue specificity
      Epithelial tissues and brain.
    • Involvement in disease
      Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:607598]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology.
    • Sequence similarities
      Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
      Contains 1 protein kinase domain.
    • Developmental stage
      Overexpressed in a subset of human mammary tumors.
    • Domain
      The cytoplasmic part of the receptor may interact with the SH2 or SH3 domains of many signal-transducing proteins.
    • Post-translational
      modifications
      Ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase.
    • Cellular localization
      Secreted and Cell membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • c erbB 3 antibody
      • c erbB3 antibody
      • Erb b2 receptor tyrosine kinase 3 antibody
      • ErbB 3 antibody
      • ERBB3 antibody
      • ERBB3 protein antibody
      • erbB3 S antibody
      • ERBB3_HUMAN antibody
      • Glial growth factor receptor antibody
      • HER 3 antibody
      • HER3 antibody
      • Human epidermal growth factor receptor 3 antibody
      • LCCS2 antibody
      • MDA BF 1 antibody
      • MGC88033 antibody
      • p180 ErbB3 antibody
      • p45 sErbB3 antibody
      • p85 sErbB3 antibody
      • proto-oncogene-like protein c ErbB 3 antibody
      • proto-oncogene-like protein c ErbB3 antibody
      • Proto-oncogene-like protein c-ErbB-3 antibody
      • Receptor tyrosine protein kinase erbB 3 antibody
      • Receptor tyrosine protein kinase erbB3 antibody
      • Receptor tyrosine-protein kinase erbB-3 antibody
      • Tyrosine kinase type cell surface receptor HER3 antibody
      • Tyrosine kinase-type cell surface receptor HER3 antibody
      • v erb b2 avian erythroblastic leukemia viral oncogene homolog 3 antibody
      • v erb b2 erythroblastic leukemia viral oncogene homolog 3 (avian) antibody
      • v erb b2 erythroblastic leukemia viral oncogene homolog 3 antibody
      see all

    Images



    • Predicted band size : 149 kDa

      Lane 1: Wild-type HAP1 whole cell lysate (20 µg)
      Lane 2: ERBB3 knockout HAP1 whole cell lysate (20 µg)
      Lane 3: MCF7 whole cell lysate (20 µg)

      Lanes 1 - 3: Merged signal (red and green). Green - ab32121 observed at 185 kDa. Red - loading control, ab9484, observed at 37 kDa.

      ab32121 was shown to specifically recognize ERBB3 in wild-type HAP1 cells along with additional cross-reactive bands. No band was observed when knock out samples were examined. Wild-type and ERBB3 knockout samples were subjected to SDS-PAGE. Ab32121 and ab9484 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/500 dilution and 1/20,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1/20,000 dilution for 1 hour at room temperature before imaging.

    • Anti-ErbB 3 antibody [E186] (ab32121) at 1/1000 dilution + MDA-MB-435 (human ductal carcinoma) whole cell lysate at 10 µg

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size : 149 kDa
    • Anti-ErbB 3 antibody [E186] (ab32121) at 1/500 dilution (unpurified) + MCF-7 cell lysate

      Predicted band size : 149 kDa
      Observed band size : 185 kDa (why is the actual band size different from the predicted?)

    References

    This product has been referenced in:
    • Humtsoe JO  et al. ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth. Oncogene 35:1554-64 (2016). Read more (PubMed: 26073080) »
    • Xu J  et al. HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib. Oncol Lett 12:5363-5369 (2016). WB ; Human . Read more (PubMed: 28105244) »

    See all 7 Publications for this product

    Customer reviews and Q&As

    Application
    Western blot
    Loading amount
    50 µg
    Gel Running Conditions
    Reduced Denaturing
    Sample
    Human Cell lysate - whole cell (iPSC-cardiomyocytes and lung adenocarcinoma cell l)
    Specification
    iPSC-cardiomyocytes and lung adenocarcinoma cell l
    Blocking step
    1:1 Odyssey blocking buffer and 1X PBS as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 100%
    Username

    Abcam user community

    Verified customer

    Submitted Aug 18 2014

    Thank you for your enquiry. I have been in touch with the source of this antibody and I have discussed the problems that you have been having with them. They consider the approach that you are proposing a good idea. They also suggested inducing the ...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up